Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Zolmitriptan
Drug ID BADD_D02393
Description Zolmitriptan is a member of the triptan class of 5-hydroxytryptamine(5-HT)1B/1D/(1F) receptor agonists used to treat acute migraine.[A462, L12978] [Sumatriptan] was the first triptan to be developed, but had poor oral bioavailability and lipophilicity. This led to the development of second-generation triptans, including [almotriptan], [eletriptan], [frovatriptan], [naratriptan], [rizatriptan], and zolmitriptan.[A193791] Triptans can be administered alone or in combination with an NSAID like [naproxen], and represent the current "gold standard" for acute migraine treatment.[A193797] Zolmitriptan was first approved by the FDA for sale by Zeneca Pharmaceuticals under the trade name Zomig® on November 25, 1997. It is currently available in both tablet and nasal spray forms.[L12978]
Indications and Usage Zolmitriptan is indicated for the acute treatment of migraine with or without auras in patients aged 18 and over.[L12978]
Marketing Status approved; investigational
ATC Code N02CC03
DrugBank ID DB00315
KEGG ID D00415
MeSH ID C089750
PubChem ID 60857
TTD Drug ID D0NG7O
NDC Product Code 64567-0016; 63548-0101; 64896-681; 64896-682; 64980-256; 68001-250; 72189-435; 65372-1145; 16571-803; 69238-2007; 65977-0050; 67835-5007; 64896-692; 65841-765; 65841-766; 64896-691; 64980-204; 69097-864; 71626-101; 72189-434; 65015-688; 46708-182; 64896-672; 68001-249; 68462-498; 60846-2384; 64896-671; 64980-203; 64980-257; 65841-768; 68382-715; 68462-497; 69097-863; 63548-0102; 63629-9575; 68382-712; 72606-567; 54864-955; 27241-022; 68382-717; 68462-499; 11722-012; 63850-4322; 45802-711; 46708-181; 46708-463; 55700-943; 55700-944; 68382-714; 69238-2006; 55111-800; 27241-021; 46708-462; 60846-2383; 65841-767; 65862-914; 65862-915; 68462-500; 71626-102; 72606-568; 65862-801; 66039-845; 16571-804
UNII 2FS66TH3YW
Synonyms zolmitriptan | 4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone | Zomig | AscoTop | Zomigoro | 311C90 | Flezol
Chemical Information
Molecular Formula C16H21N3O2
CAS Registry Number 139264-17-8
SMILES CN(C)CCC1=CNC2=C1C=C(C=C2)CC3COC(=O)N3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tachypnoea22.02.01.0140.000677%Not Available
Tardive dyskinesia17.01.02.012--Not Available
Tenderness08.01.08.005--Not Available
Tenosynovitis15.07.01.004--Not Available
Tension19.06.02.005--Not Available
Tetany05.04.02.003; 15.05.03.013; 14.04.01.005--Not Available
Thinking abnormal19.10.03.001; 17.02.05.023--Not Available
Thirst08.01.09.021; 14.03.02.007--Not Available
Throat tightness22.12.03.031; 19.01.02.0050.000677%Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombophlebitis24.01.02.001--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tongue disorder07.14.01.002--Not Available
Tongue oedema23.04.01.009; 10.01.05.008; 07.14.02.007--Not Available
Transient ischaemic attack24.04.06.005; 17.08.04.0010.000677%
Tremor17.01.06.002--
Ulcer08.03.06.001--Not Available
Unintended pregnancy18.08.01.001--Not Available
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.001--
Uterine disorder21.07.01.006--Not Available
Uterine leiomyoma21.07.02.004; 16.04.02.001--Not Available
Vaginal infection21.14.02.002; 11.01.10.002--
Vasospasm24.04.02.002--Not Available
Ventricular fibrillation02.03.04.008--
Ventricular tachycardia02.03.04.010--
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.0070.002708%
The 8th Page    First    Pre   8 9 10    Next   Last    Total 10 Pages